A Study of the Response to AG-86893 in Patients With Pterygium Hyperemia
Status:
Completed
Trial end date:
2019-10-25
Target enrollment:
Participant gender:
Summary
A pterygium is a wing-shaped, benign tissue growth which forms on the surface of the
conjunctiva and grows towards the cornea. It can eventually lead to vision impairment. The
precise cause of pterygium formation is unknown but new blood vessel growth and fibroblastic
structures are characteristics of the disease. AG-86893 is an eye drop being developed to
treat hyperemia (redness) and growth of the pterygium.
Hypothesis
1. AG-86893 dosed three times daily for 28 consecutive days has an acceptable safety
profile as measured by the incidence and severity of adverse events (AEs) compared with
vehicle
2. At least 1 concentration of AG-86893 is effective, as measured by the mean change from
baseline in conjunctival hyperemia (redness), compared with vehicle